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A simple, sensitive cost-effective and reproducible reverse phase high performance liquid 
chromatographic (HPLC) method was developed to quantitate plasma levels of proguanil 
(PGN) and its active metabolite, cycloguanil (CGN) in order to conduct single dose 
pharmacokinetic studies. The drug and the internal standard were added to plasma samples, 
vortexed and rendered alkaline with 2 M NaoH and the samples extracted with ether, 
evaporated to dryness and the residue was reconstituted in methanol, whirlmixed before 
injecting an aliquot onto the HPLC system. The calibration plots were linear over the 
concentration range up to 4.0 µg /ml. The correlation coefficients (r) were of the order of 0.99 
and above for both PGN and CGN. The ion pair method was carried out on a 5 µ reverse 
phase C-18 column, using perchlorate ion as the counter ion and ultra violet detection at 254 
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nm. The method was reproducible with coefficient of variation for PGN and CGN, being less 
than 4.0 %. PGN was well resolved from its active metabolite, CGN, and the internal 
standard, pyrimethamine. The limit of detection of PGN was 10 ng /ml and the recovery was 
greater than 95% in plasma.  The analytical method therefore, exhibits good precision and 
sensitivity in detecting and quantifying PGN and CGN and has been demonstrated to be 
suitable for the pharmacokinetic studies of proguanil. The clinical applicability of the method 
was assessed by the preliminary pharmacokinetic study of PGN and CGN, in fifteen healthy 
volunteers. The in vivo study was carried out according to a single dose randomized design.  
 
































Proguanil is a synthetic biguanide derivative of pyrimidine. It is widely used in 
chemoprophylaxis of malaria. It is chronically administered for malaria prophylaxis in sickle cell 
patients and in pregnant women in Nigeria (1). Proguanil has found use in combination with 






















Fig 1: Structures of Proguanil and Cycloguanil 
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Proguanil (Fig. 1) is well absorbed, achieving Cmax within 2 to 5 hours (2, 3). The drug is 
considered a prodrug, since it is metabolized in the liver to the dihydrofolate reductase (DHFR) 
inhibitor cycloguanil (Fig. 1), but there are also recent indications that proguanil itself enhances 
the activity of atovaquone (4). Nevertheless, transformation to cycloguanil is rapid, its Cmax 
occurs 1 hour after the Cmax of proguanil, and Cmax of the inactive metabolite, 4-
chlorophenylbigunanide occurs a further 1 hour later. The metabolism of proguanil is mediated 
partly by CYP 3A4 but mainly by CYP 2C19 (5). There is considerable genetic polymorphism of 
CYP 2C19 enzyme, with up to 20 % poor metabolisers in Asian and African populations (6,7). 
Poor metabolisers have very low or undetectable plasma concentrations of cycloguanil during 
prophylaxis. This polymorphism may be the cause of failure of prophylaxis by poor 
metabolisers, but due to large variability in data a clear association between CYP 2C19 activity 
and efficaciousness of prophylaxis has not yet been demonstrated (6,7). The half-life of 
proguanil is 12 to 20 hours in patients with malaria and healthy volunteers (2,4), but longer in 
poor metabolisers (2). The half life of cycloguanil is approximately 12 hours. 
 
Due to the renewed interest in the use of proguanil in prophylactic treatment of malaria it 
is worthwhile to develop an HPLC method suitable for its pharmacokinetic studies, hence, this 
study. There are various methods for the determination of proguanil and its metabolites in the 
body ranging from colorimetric, microbiological and chromatographic methods. 
The colorimetric and bioassay method of analysis as described by (8, 9) lacked specificity and 
sensitivity. They are, therefore, of little value in pharmacokinetic studies. Moody et al. (1980) 
(10) reported a chromatographic method for the analysis of proguanil in the biological fluid 
using a reversed phase, ion-pair high performance liquid chromatographic (HPLC) technique. 
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Specific quantitation was obtained but the assay sensitivity was inadequate for the determination 
of the metabolites. The methods of Bergqvisty et al (1998) (11) and Kusaka et al (1996)(12)  
were less sensitive and expensive. 
 
The method developed by Paci et al (2002) (13) for the simultaneous determination of 
proguanil and chloroquine was not applicable in biological fluid but for the determination of the 
drugs in a dosage form. A very sensitive method with a short analysis time involving a 
combination with mass spectrometer was developed by Leveque et al (2006) (14). This method 
may not be suitable in most developing countries where a mass spectrometer is not affordable. 
Due to some of these inconsistencies on the analytical data of proguanil and inter laboratory 
differences, the report of WHO informal consultation on the use of antimalarial drugs (2001) 
(15) adjudged proguanil to have limited pharmacokinetic data in literature.  The method 
described here is simple, sensitive, selective, and cost-effective and allows for routine analysis of 




Chemicals and reagents: 
 
Proguanil and cycloguanil were obtained from Imperial Chemical Industries Ltd, Great 
Britain, while pyrimethamine was obtained from Swiss Pharma Nigeria (Lagos, Nigeria), 
Proguanil hydrochloride tablets, PaludrineR (Astra Zeneca, Germany) were purchased from a 
retail pharmacy in Nigeria. HPLC grade acetonitrile and methanol, and analytical grade 
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diethylether, perchloric acid, sodium hydroxide and hydrochloric acid were purchased from 
Sigma (Sigma-Aldrich chemical company, Germany).  
Subjects 
Fifteen healthy volunteers (10 males and 5 females) between the ages of 22 and 30 years 
weighing 56 to 71 Kg were enrolled into the study after giving written informed consent. They 
were judged healthy by a physician on the basis of history, clinical examination, biochemical, 
hematological and electrocardiographic screening prior to entry into the study. Approval was 
obtained from the Obafemi Awolowo University Teaching Hospitals Research Ethics Board and 
safety committee. 
Sample collection 
In period 1 blood samples (5 ml) were withdrawn by venipuncture from the forearm of 
each subject prior to and at 1,2,4,6,8,12,24,36, and 48 hours after drug administration into 
heparinized tubes. They were immediately centrifuged (1500 g at 20 OC for ten minutes) to 
separate plasma. The plasma aliquots were stored at -20 OC until analyzed. 
In period 2 blood samples (5 ml) were withdrawn from the forearm of each volunteer by 
venipuncture into  heparinised tubes immediately before the 9th dose of efavirenz and co 
administration with single oral dose of 300 mg proguanil, and at 1,2,4,6,8,12,24,36 and 48 hrs 
after drug administration. They were centrifuged to separate plasma and stored at -20 oC until 
analyzed. 
Analysis of Samples 
The plasma samples were analyzed for proguanil and cycloguanil to obtain proguanil 
baseline pharmacokinetics in period 1, and analyzed for proguanil and its metabolite in the 
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presence of efavirenz in period 2. The HPLC method used for the analysis was a modification of 
that described by Ebeshi et al., (2005). The column used was a Hypersil ODS (C-18) 5µm 
particle size with dimension of 250 x 4.6 mm I.D. A mobile phase consisting of methanol: 
acetonitrile: 0.5 % ammonium acetate (40:5:55) containing 75 mM/L perchloric acid was 
pumped through the column at a flow rate of 1.2 ml/min. The pH of the mobile phase was 2.9 
and the chromatogram was run at ambient temperature. 
Analytical procedure 
Calibration curve in plasma:  
1 ml of blank plasma samples were placed in extraction tubes; and varying amounts of the 
stock solutions  (100 µg/mL) of proguanil and cycloguanil were added to give concentration 
range between 0.1 – 3 µg/ml for the two compounds. 20 µL of the internal standard, 
pyrimethamine (100µg/ml) was added to each tube. The stock solutions (1 mg/ml each) of 
proguanil and cycloguanil were prepared in methanol, while that of pyrimethamine was prepared 
in acetonitrile. The plasma samples were rendered alkaline with 2 M NaOH (0.5 ml) and 
whirlmixed for 1 min. Then 3 ml of ether was added to each of the samples and whirlmixed for 1 
min after which the tubes were centrifuged at 1500 g for 10 min. The upper organic layer was 
aspirated into another tube. The extraction with ether was repeated twice and pooled extract was 
evaporated to dryness in a water bath at 40oC. The residue was reconstituted in 100 µL of 
methanol and whirlmixed before injecting 50 µL onto the HPLC. The peak area ratio was plotted 
against the concentration of each of the compounds injected. The regression analysis was carried 
out with the aid of a computer. 
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Analysis of test plasma samples:  
To 1 ml of plasma sample in extraction tube, 20 µL of the internal standard was added. The 
extraction and reconstitution followed as described above before injecting 50 µL onto the HPLC. 
Precision studies in plasma:  
Intra-day Precision Studies: Two sets, each set consisting of six centrifuge tubes were used. 
Each tube in the first set contained 1 ml of blank plasma spiked with the stock solution of 
proguanil and cycloguanil to give a concentration of 0.5 µg/ mL.The second set also contained 1 
ml of blank plasma spiked with stock solutions of the two compounds to give a concentration of 
2µg/mL of each. All the samples were then spiked with 20 µL of the internal standard solution. 
Extraction followed under alkaline conditions as earlier described. The residue was reconstituted 
in 100 µL methanol, whirlmixed before 50 µL was injected onto the HPLC. The coefficient of 
variation of each set was computed. 
Inter-day Precision Studies:  
The procedure above was followed but two samples for each set were analyzed daily for 
three days. 
Recovery Studies in Plasma:  
The procedure described for precision studies was followed but coefficients of variation of 
replicate samples were not determined. Rather the stock solutions were diluted in such a way as 
to give concentrations equivalent to extracted 0.5 µg /mL and 2.0 µg /mL for the two 
compounds. The solutions were injected directly onto the chromatograph. To determine the 
recovery, the peak areas obtained with the extraction and direct injection methods were 
compared. 
 JPRHC | July 2009 | Vol. 1 | No.1 | 2-24                                                                           Page 10 
 
 
Accuracy of method: 
The accuracy of the analytical method for each of proguanil and cycloguanil was evaluated 
from the percentage ratio of the experimentally determined concentration to that of the actual 
drug concentration.  
Chromatographic conditions and instrumentation 
The HPLC equipment was an AKTA system ( Amersham Pharmacia Biotech, Uppsala 
Sweden) consisting of binary pumps (P-900) fitted with a gradient mixer and a variable 
wavelength (200–800 nm) ultraviolet–visible detector (model UV-900). Sample injection was 
through a model INV-907 valve fitted with a 50µL loop. The detector output was linked to a 
computer via a brain box interphase (AKTA instrument), which transforms signals from the 
detector to the computer that eventually records the chromatograms. Chromatographic separation 
was achieved at ambient temperature on Eclipse – XDB (C-18) (Agilent Technologies, Palo 
Alto, CA, USA), a 5µm particle size C-18 column (200mm×4.6mm I.D.). A mobile phase 
consisting of methanol: acetonitrile: 0.5 % ammonium acetate (40:5:55) containing 75 mM/L 
perchloric acid was pumped through the column at a flow rate of 1.2 ml/min. The pH of the 
mobile phase was 2.9 and the chromatogram was run at ambient temperature. The column 
effluent was monitored with the detector set at 254 nm. Vortex mixer (Gallenkamp, London, 
UK) and centrifuge (Gallenkamp) were used in the extraction procedure. 
Selectivity 
Various antimalarial drugs and other drugs commonly co-administered with antimalarials 
such as amodiaquine, chloroquine, quinine, primaquine, cycloguanil, paracetamol, 
chlopheniramine and promethazine were evaluated for interference with the assay. Drug-free 
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plasma was spiked with therapeutic concentrations of the drugs followed by extraction and 
analysis as described. 
 Application of the analytic method 
Fifteen healthy volunteer who had not been taking any other drug, received a single oral 
dose of 300 mg proguanil. Thereafter, venous blood samples (5 ml) were collected into 
heparinised tubes just before and at 1, 2, 4, 6, 8, 12, 24, 36 and 48 h after drug administration. 
The blood samples were centrifuged at 2000 x g for 15 min to obtain the plasma which was 
analyzed for PGN and CGN concentrations using 1 ml aliquots of plasma samples and following 
the procedures described.  
 The maximum plasma drug concentration (Cmax) was estimated by visual inspection of 
the concentration – time data. The total area under plasma concentration vs. time curve (AUCT) 
was obtained from a sum of AUC0-t and Ct/β where AUC0-t was derived using the linear 
trapezoid method up to the last time point concentration (Ct). β is the elimination rate constant 
obtained by linear regression analysis of the terminal phase of the curve. 
 
RESULTS 
Typical chromatograms obtained from the described HPLC method are shown in Fig. 2. 
These demonstrate that the peak of PGN was well resolved from the internal standard as well as 
from CGN. The retention times (tR) of cycloguanil, ISTD and proguanil were 6.9, 8.6, and 10.7 
min respectively. There was no interference from endogenous compounds. Also no interference 
with the peaks of the compounds was found from chloroquine, primaquine, paracetamol, 
chlopheniramine, and promethazine. The minimum detectable concentrations, taken as a 
concentration giving a peak three times the baseline noise was 5 ng/ml for PGN and CGN and 30 
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ng/ml for pyrimethamine. Linear curves were obtained for proguanil and cycloguanil in plasma 
with correlation coefficients of not less than 0.99 for each of the curves. (Fig. 3). The results of 
the precision as well as the recovery and accuracy of the analytical method for both PGN and 
CGN are shown in Table1. While the pharmacokinetic parameters derived from the plasma 
concentration-time profiles are presented in Table 2 a and b. The mean Tmax of proguanil was 2.8 
± 0.99 h, while the peak plasma concentrations (Cmax) ranged from 2.20 to 3.00 mg/L with a 
mean of 2.55 ± 0.24 mg/L. The drug had an elimination half-life of 16.50 ± 4.55 h, a total 
clearance (Cl/F) of 7.08 ± 1.97 L/h (range 4.14 – 10.98 L/h) and an apparent volume of 
distribution (Vd/F) of 160.54 ± 36.06 L (range 109.89 – 234.09 L). The AUCT varied between 
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Fig. 2a HPLC chromatograms: A) extracted spiked plasma containing ISTD, B) extracted spiked 
plasma containing PGN, C) extracted spiked plasma containing CGN and ISTD, D) extracted 
spiked plasma containing PGN and ISTD. 
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Fig 2b: HPLC chromatograms: E) 2h plasma extract from a volunteer, F) 4 h plasma extract from 
a volunteer, G) extracted spiked plasma containing ISTD, PGN and CGN,  H) 6 h plasma extract 
from a volunteer.  
 
Table 1a 
Result of precision study in plasma. 
Sample  Concentration   Coefficient of variation  n 
   (µgml-1)    % 
Intraday 
Proguanil  0.5    3.86     6 
   2.0    3.57     6 
 
Cycloguanil  0.5    3.75     6 
   2.0    3.64     6 
Interday 
Proguanil  0.5    3.62     6 
   2.0    3.48     6 
 
Cycloguanil  0.5    3.59     6 
   2.0    3.40     6 
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Table 1b:  
Result of Recovery in Plasma 
Sample  Concentration   % Recovered ±SD  n 
   (µgml-1) 
Proguanil  0.5    95.2±4.8   6 
   2.0    96.5±3.3   6 
 
Cycloguanil  0.5    85.4±2.6   6 
   2.0    80.7±3.8   6 
 
Table 1c:  
Accuracy of Analytical Method  
 
Sample  Concentration   % Mean ± SD   n 
   (µgml-1) 
Proguanil  0.5    90.0 ± 6.0   6 
   2.0    92.2 ± 2.5   6 
Cycloguanil  0.5    92.8 ± 5.0   6 
   2.0    92.8 ± 2.8   6 
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Table 2a 
Derived pharmacokinetic parameters of proguanil following single oral administration of 300 mg 
dose of proguanil hydrochloride to each of fifteen healthy volunteers 
 















BK 64 2 2.60 57.74 20.51 5.20 153.77 
AO 59 2 2.40 38.37 15.14 7.82 170.80 
TF 66 2 2.80 47.26 12.00 6.35 109.89 
IP 70 4 3.00 54.94 16.97 5.46 133.61 
OS 65 2 2.40 45.30 19.63 6.62 187.50 
FE 68 4 2.40 47.06 12.00 6.37 110.38 
BF 62 4 2.80 72.50 24.95 4.14 148.97 
YF 58 2 2.20 28.99 10.34 10.35 154.30 


















































        
Mean 62.67 2.80 2.55 45.58 16.50 7.08 160.54 
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Table 2b 
Pharmacokinetic parameters of proguanil metabolite (cycloguanil) following single oral 











(  h.) 
AUC0-48(met)/ 
AUC0-48(drug) 
   
       
BK 64 4.0 0.48 9.52 16.75 0.18 
AO 59 4.0 0.56 12.74 16.71 0.29 
TF 66 4.0 0.70 16.82 16.80 0.32 
IP 70 6.0   0.72 23.07 19.60 0.43 
OS 65 4.0 0.40 7.42 16.78 0.19 
FE 68 4.0 0.68 18.76 18.55 0.38 
BF 62 6.0 0.76 22.71 19.30 0.38 
YF 58 4.0 0.70 22.15 19.67 0.69 












































       
Mean 62.67 4.40 0.61 16.19 18.03 0.38 








The extraction procedure employed in this study produced clean and clear supernatants from 
plasma as there was no interference from endogenous compounds. All the three compounds 
(proguanil, cycloguanil and ISTD) were completely resolved to baseline and samples could be 
injected at 12-min intervals. Sulphadoxine–pyrimethamine is not used in combination with 
proguanil in malaria chemotherapy; therefore, the possibility of interference from the internal 
standard is remote. Results of the assessments of precision, recovery and accuracy given in Table 
1(a,b,c) show that the method has a high degree of precision as the intraday and inter-day 
coefficients of variation were not greater than 9% at low and high concentrations of the three 
compounds. The recovery of over 90% for PGN and CGN by the analytical method shows that 
the sample preparation and extraction procedure was efficient for the compounds. Evidence of 
accuracy of the method is demonstrated in the results which ranged between 92 and 97% for the 
compounds at low and high concentrations. It was necessary to precipitate the protein so as to 
release more of the drugs since proguanil (16,17) is highly bound to plasma proteins. This was 
achieved by adding 200µL of perchloric acid which was enough to denature the proteins before 
proceeding with the extraction of the drug. 
 
The method reported here retains the sensitivity and precision of other previous methods for the 
analysis of the drug but it also has the advantage of being simple, cost-effective and devoid of 
any cumbersome extraction procedure. The composition of the mobile phase also proves the 
simplicity of the method. The mobile phase consisted mainly (75%) of potassium dihydrogen 
phosphate solution and small amounts of methanol and acetonitrile which are commonly 
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available, thus, making the method cost-effective and affordable. The rapidity of the method is 
underlined by the relatively short analysis time. The maximum time required for a sample 
treatment prior to injection was 10 min, which is much shorter than the analysis time of 62 and 
40 min reported by other workers (10,12) for the analysis of proguanil in plasma. 
To evaluate the application of this method in pharmacokinetic studies, concentrations of 
PGN and CGN were measured in plasma of fifteen volunteers after a single oral dose of PGN 
(300mg). The results from this present study indicate that proguanil is rapidly absorbed after oral 
administration in all subjects with a Tmax in the range of 2 to 4 h. The pharmacokinetic 
parameters obtained for proguanil and cycloguanil (Table 2a and 2b) such as Tmax, elimination 




In conclusion, the HPLC method described is very simple, reproducible, sensitive and rapid. The 
method is also accurate, selective and cost-effective. It will facilitate the conducting of 
pharmacokinetic studies on proguanil. 
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